Bioanalytical Method Development and Validation for Estimation of Daunorubicin and Cytarabine in Blood Plasma by Using RP-HPLC by Agrawal, Ashish & Sharma, Manoj
Agrawal et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2019; 9(4):366-373 
 
ISSN: 2250-1177                                                                                  [366]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.07.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                     Research Article 
Bioanalytical Method Development and Validation for Estimation of 
Daunorubicin and Cytarabine in Blood Plasma by Using RP-HPLC 
Ashish Agrawal* 1, Manoj Sharma 2, 
1 Research Scholar, Bhagwant University, Ajmer (Rajesthan), India 
2 School of Studies in Pharmaceutical Sciences, Jiwaji University, Gwalior, India 
 
ABSTRACT 
A simple, sensitive and selective RP-HPLC method was developed for estimation of Daunorubicin and Cytarabine in combined formulation by 
isocratically using 20 mM KH 2 PO 4 : acetonitrile (pH 2.5) in the ratio of 20:80 v/v as mobile phase, Prontosil C-18 column (4.6 x 250mm, 
5μparticle size) column as stationary phase and chromatogram was recorded at 254nm.  The validation studies are carried out and it’s fulfilling 
ICH requirements. The method is found to be specific, linear, precise (including both intra- and inter- day precision), accurate and robust. This 
proposed method may represent a valuable aid in the laboratory monitoring of the toxicity of anticancer chemotherapy.  
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INTRODUCTION:  
Leukemia is a malignant disorder of bone marrow and blood, 
and is the most widespread cancer in children and teenagers. 
It accounts for about 1/3rd of all cancers in children, acute 
myelogenous leukemia (AML) being the most common type. 
Leukemia therapy relies generally on combination 
chemotherapy utilizing a number of different anticancer 
drugs1-20.  
Extensive literature survey reveals that very few 
spectrophotometric and chromatographic methods have 
been reported. But still no method has been reported for the 
individual as well as simultaneous estimation of these drugs. 
So it goes very important to develop a simple, precise, and 
accurate, analytical method for estimation of Daunorubicin 
and Cytarabine individual as well as simultaneous in bulk 
and pharmaceutical dosage and Blood Plasma using RP-
HPLC.21-43 
MATERIAL & METHODS 
Chemicals and Reagents 
HPLC grade Acetonitrile, KH 2 PO 4 l and Acetic acid were 
purchased from Merck, while HPLC grade water was 
purchased from Qualigens, Mumbai (India).  The drugs ATRA 
and MTX were received as gift samples. Marketed tablet wih 
brand name Vyxeos is used for analysis having Daunorubicin 
– 44mg and Cytarabine – 100mg. 
Identification of drugs 
The identification as well as Authentification of both the 
procured drugs was done by melting point and FT-IR 
spectroscopy. The observed results of melting point are 
shown in Table 1 and for IR Spectra results shown in tablet 
2, 3 and Fig. 1 & 2.   
Determination of solubility of both drugs in different 
solvents. 
Solubility of Daunorubicin and Cytarabine was observed by 
dissolving them in different solvents and the observed 
results are shown in Table 4. 
RP-HPLC method development for the Simultaneous 
estimation of both drugs 
Selection of Chromatographic Method 
Proper selection of the chromatographic method depends 
upon the nature of the sample (ionic/ionisable/neutral), its 
molecular weight and solubility. Optimized chromatographic 
conditions were obtained shown in Table 5. 
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Selection of Precipitating Agent  
Selection of precipitation agent is based on the solubility of 
drug and good protein precipitation property. Daunorubicin 
and Cytarabine soluble in Acetonitrile and having good 
precipitating property so the Acetonitrile was selected as the 
protein precipitation and extraction agent 
Selection of Mobile Phase  
Initially to estimate Daunorubicin and Cytarabine in fix 
dosage form number of mobile phase in different ratio were 
tried. A result was shown in Table 5. Taking into 
consideration the system suitability parameter like RT, 
Tailing factor, No. of theoretical plates and HETP, the mobile 
phase found to be most suitable for analysis was 20 mM 
KH2PO4: acetonitrile (pH 2.5) in the ratio of 20:80 v/v. The 
mobile phase was filtered through 0.45 filter paper to 
remove particulate matter and then degassed by sonication. 
Flow rate employed for analysis was 1.0 ml/min.     
Selection of Diluent 
Diluent used for preparation of sample were compatible 
with mobile phase and no any significant affect retention and 
resolution of analyte. After various trials Acetonitrile was 
used as diluents. 
Extraction of drug sample  
Accurately weighed 10 mg of Daunorubicin was transferred 
into 50 ml volumetric flasks separately and dissolved in 10 
ml of plasma, then volume was made up to 50 ml with 
acetonitrile and vortex it to get complete precipitation of 
plasma protein. Stand it aside for few minute, precipitate of 
protein settled down then collect the supernatant layer and 
add 10 ml of acetonitrile in precipitate to complete removal 
of drug. Centrifuge the collected supernatant layer at 6000 
rpm for 7 min at 4oC and then filtered by whatmann filter 
paper (no.41). Concentration of Daunorubicin in acetonitrile 
was 200 µg/ml. (stock- A) 
Preparation of Sub Stock Solution  
5 ml of solution was taken from stock-A of Daunorubicin and 
transferred into 10 ml volumetric flask separately and 
diluted up to 10 ml with diluent (Acetonitrile) to give 
concentration of 100 µg/ml (Stock-B). 
Preparation of Different Solution 
0.1ml, 0.2ml, 0.3ml, 0.4ml and 0.5ml of stock-B was taken 
separately in 10 ml volumetric flask and volume was made 
up to 10ml with (Acetonitrile). This gives the solutions of 
1µg/ml, 2µg/ml, 3µg/ml, 4µg/ml, 5µg/ml for drug. In same 
manner 2µg/ml, 4µg/ml, 6µg/ml, 8µg/ml, 10µg/ml of 
Cytarabine also prepared. 
Linearity and Calibration Graph 
To establish the linearity of analytical method, a series of 
dilution ranging from 5-25 g/ml was prepared. All the 
solution were filtered through 0.2m membrane filter and 
injected, chromatograms were recorded at 315 nm and it 
was repeat for three times. A calibration graph was plotted 
between the mean peak area and respective concentration 
and regression equation was derived. Graphs shown in fig 3-
6. 
 System Suitability Parameters 
Separation variables were set and mobile phase was allowed 
to saturate the column at 1.00 ml/min. After complete 
saturation of column, three replicates of working standard of 
Daunorubicin 2g/ml and 4g/ml Cytarabine was injected 
separately. Peak report and column performance report 
were recorded for all chromatogram. (Table No. 6) 
Laboratory Sample Analysis 
The commercial tablet formulation of Daunorubicin is 
available in the strength of 10 mg. Based on this different 
standard solutions were prepared for quantitative analysis, 
which gives satisfactory results. Stock solution was prepared 
in the same manner. Further dilutions were made to prepare 
the mixed standard of desired concentration. (Table No. 7) 
Method Validation 
On the basis of fixed parameters the method of estimation 
was validated for following parameters. 
Linearity 
The calibration plot was contracted after analysis of five 
different (from 1 to 5 µg/ ml) and (2 to 10µg/ ml) 
concentrations and areas for each concentration were 
recorded three times, and mean area was calculated. The 
regression equation and correlation coefficient of curve are 
given and SD and RSD were calculated and results shows in 
table 8.  
Specificity 
Specificity of the method was carried out to assess 
unequivocally the analyte presence of the components that 
might be expected to be present, such as impurities, 
degradation products and matrix components. Results show 
in figure 7 and 8.  
Accuracy 
Recovery studies were performed to validate the accuracy of 
developed method to preanalysed sample solution, a definite 
concentration of standard drug (80%, 100%, and 120%) was 
added and then its recovery was analyzed. Results shown in 
table 9.  
Precision 
The stock solution was prepared. The precision are 
established in three differences: (Table No. 10) 
1. Repeatability 
2. Intermediate precision 
a) Day to Day 
b) Analyst to Analyst 
3. Reproducibility 
Repeatability 
The repeatability was performed for five replicate at five 
concentrations in linearity range 1, 2, 3, 4 and 5g/ml for 
Daunorubicin and 2, 4, 6, 8 and 10g/ml Cytarabine for 
indicates the precision under the same operating condition 
over short interval time. Results of repeatability are 
reported in table respectively. 
Intermidiate Precision 
Day To Day Precision 
Intermediate precision was also performed within 
laboratory variation on different days in five replicate at five 
concentrations. Results of day to day intermediate precision 
for Daunorubicin and Cytarabine reported in table 
respectively.    
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Robustness 
As per ICH norms, small, but deliberate variations in 
concentration of the mobile phase were made to check the 
method’s capacity to remain unaffected. The ratio of mobile 
phase was change from, 20mM Phosphate Buffer: 
acetonitrile (20:80 % v/v), to (15:85 % v/v).Results of 
robustness are reported in table 11. 
Detection Limit and Quantitation Limit 
The LOD and LOQ of developed method was calculated based 
on the standard deviation of response and slope of the 
linearity curve. (Table No. 12) 
Analysis of Injectable formulation 
Amount equal to 10 mg of CYTA was taken in 100-ml 
volumetric flask. This was than dissolve in 13 ml of plasma 
by sonication for about 10 minutes. The volume is made up 
to the mark by mobile phase and filtered by whatmann filter 
paper (no.41) and the filtrate was used to prepare samples 
of different concentration. Results of tablet analysis are 
reported in table no. 13. 
RESULS 
Identification of drugs by Melting point determination 
and IR Spectroscopy 
Melting point of drugs was determined by using Digital 
melting point apparatus. 
Table 1:  Melting Point of Drugs 
Drug Name Melting Point Standard Value  
Cytarabine 211-214°C 212-213°C 
Daunorubicin 206-210°C 208-209°C 
  
 
IR Spectra of Daunorubicin  
 
Figure No. 1 FT-IR Spectra of Daunorubicin 
Table 2: IR interpretation of Daunorubicin 
Group Observed Frequency (cm -1) Standard Range (cm-1) 
O–H s at c ring 3324.77 3300-3010 
C=O s at b ring 1667.97 1744-1650 
NH2 sc 1601.51 1661-1550 
 
IR Spectra of Cytarabine 
 
Figure No.2 FT-IR Spectra of Cytarabine 
Table 3: IR interpretation of Cytarabine 
Group Observed Frequency (cm -1) Standard Range (cm-1) 
NH and OH stretching 3489.47 3300-3500 
CH stretching 2917.33 2800-3000 
C=O stretching 1577.72 1550-1650 
C=N and C=C stretching 1501.27 1500-1400 
C-O stretching 1268.41 1220-1300 
C-H bonding 759.12 700-800 
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Determination of solubility of both drugs in different solvents 
Solubility of Daunorubicin and Cytarabine was observed by dissolving them in different solvents and the observed results are 
shown in Table. 
Table 4: Solubility of drugs in different solvents 
Solvent Daunorubicin Cytarabine 
Water Sparingly soluble Soluble  
Methanol/ Ethanol Soluble  Sparingly soluble 
Acetonitrile Sparingly soluble Sparingly soluble 
Ether sparingly soluble Sparingly soluble 
0.1 N HCl Soluble Sparingly soluble 
0.1 N NaOH Soluble Sparingly soluble 
chloroform Insoluble  Sparingly soluble 
 
Selection of Chromatographic Method: 
Optimized chromatographic conditions were obtained shown in Table. 
Table 5:  Optimized chromatographic conditions 
Variable Condition 
Column  
 Dimension. 250mm x 4.60mm 
Particle Size 5 
Bonded Phase Octadecylsilane (C18) 
Mobile Phase  
                       0.004M NaH2PO4 15 
Acetonitrile 85 
Diluent Acetonitrile 
Flow rate 1.2 ml/min 
Temperature Ambient 
Sample Size  20 l 
Detection wavelength  340mm 
Retention time  
Methotrexate 1.95 ± 0.2min. 
                      Tretinoin 8.98± 0.4min. 
 
SYSTEM SUITABILITY 
The system suitability parameter was carried out to verify that the analytical system was working properly and could give 
accurate and precise result. The six replicates of reference standard, 5g/ml of Daunorubicin and Cytarabine were injected 
separately and chromatogram was recorded. The result of system suitability parameter is reported in table. 
TABLE 6: Results of System Suitability Parameters 
PARAMETERS Daunorubicin Cytarabine 
No. of Theoretical Plates 3561.833±8.377 3546.667±9.668 
Tailing Factor 1.163±0.045 1.195±0.059 
Retention time 7.924±0.001 11.185±0.045 
 
Laboratory Sample Analyses 
The commercial tablet formulation of Daunorubicin is available in the strength of 10 mg. Based on this different standard 
solutions were prepared for quantitative analysis, which gives satisfactory results, shows in table.  
Table 7:  Laboratory Sample Analyses 
Standard Number     Concentration of 
DAUN  (g/ml) 
    Concentration of 
CYTA  (g/ml) 
1. 1 2 
2. 2 4 
3. 3 6 
4. 4 8 
5. 5 10 
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Method Validation 
Linearity 
Different levels of standard solutions were prepared and injected into the HPLC and the chromatogram was recorded. The 
results of linearity are reported in table. 
TABLE 8: Results of Linearity of Daunorubicin and Cytarabine  
PARAMETER Daunorubicin Cytarabine 
Concentration (μg/ml) 1-5 2-10 
Correlation Coefficient (r2)* 0.999 0.998 
Slope (m)* 360.9 320.3 
Intercept (c)* -9.181 66.03 
*value of five replicate 
 
 
Fig. 3: Calibration Curve of Daunorubicin 
 
Fig. 4: Chromatogram of Daunorubicin 
 
Fig. 5: Calibration Curve of Cytarabine 
 
Fig. 6: Chromatogram of Cytarabine 
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SPECIFICITY 
Specificity of the method was determined and the peaks of plasma, diluent, mobile phase and excipient of physical mixture did 
not interfere with standard peaks of Daunorubicin and Cytarabine.   
.  
Fig. 7: Chromatogram of blank with plasma 
 
Fig. 8: Chromatogram of Both the drugs 
ACCURACY 
The validity and reliability of proposed methods were assessed by recovery studies. The recovery of added standards (80%, 
100% and 120%) was found at three replicate and three concentrations level. The value of % means just close to 100, SD and % 
RSD are less than 2 indicate the accuracy of method. Result of recovery study shown in table. 
TABLE 9: RESULTS OF RECOVERY STUDY 
% LEVEL % MEAN±SD* 
 Daunorubicin Cytarabine 
80% 98.96±0.325 99.491±0.402 
100% 99.237±0.454 100.472±0.142 
120% 98.651±0.916 99.892±0.153 
* Value of three replicate and three concentrations. 
PRECISION 
Precision was determined by repeatability and Intermediate precision of drug. Repeatability result indicates the precision 
under the same operating condition over short interval time. The intermediate precision study is expressed within laboratory 
variation on different days and analyst to analyst variation by different analyst. The value of SD and %RSD are less than 2 
indicate the precision of method. Result of precision shown in table. 
TABLE 10 RESULTS OF PRECISION 
PARAMETER 
% MEAN±SD* 
Daunorubicin Cytarabine 
Repeatability 100.198±0.045 99.778±0.029 
             Intermediate precision  
Day to day precision 99.781 ±0.041 99.862±0.035 
* Value of five replicate and five concentrations 
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ROBUSTNESS 
The robustness of developed method was checked by 
changing in the deliberate variation in solvent. Result of 
robustness shown in table. 
TABLE 11: RESULTS OF ROBUSTNESS 
PARAMETER 
% MEAN±SD* 
Daunorubicin Cytarabine 
Robustness 99.158±1.687 99.844±0.051 
* Value of five replicate and five concentrations 
LOD AND LOQ 
Detection limit and quantitation limit of described method 
were observed as 0.12g/ml and 0.35 g/ml respectively 
and quantitation limit 0.36g/ml and 0.95g/ml 
respectively based on the SD of response and slope, which 
meet the requirement of new method. Result shown in table. 
TABLE 12: LOD and LOQ of DAUN and CYTA 
Name LOD (g/ml) LOQ (g/ml) 
DAUN 0.12 0.35 
CYTA 0.36 0.95 
 
ASSAY OF TABLET FORMULATION 
The results of the analysis of Injectable formulation were 
reported. The assay value of drugs was close to 100, SD and 
% RSD are less than 2 indicate the no interference of 
excipient in the estimation of drugs. 
TABLE 13: Analysis of Injectable Sample 
 DAUN* CYTA* 
Label Claim (mg) 44mg 100mg 
% Found (mg) 43.45 99.85 
% Assay  98.75 99.85 
% RSD 1.365 1.112 
*Average of three determination 
DISCUSSION: 
.A simple, rapid, accurate and precise Bioanalytical Method 
Development and Validation for Estimation of Daunorubicin 
and Cytarabine in Blood Plasma by Using RP-HPLC. The RP-
HPLC method was developed for estimation of Daunorubicin 
and Cytarabine in combined formulation by isocratically 
using 20 mM KH2PO4: acetonitrile (pH 2.5) in the ratio of 
20:80 v/v as mobile phase, Prontosil C-18 column (4.6 x 
250mm, 5μparticle size) column as stationary phase and 
chromatogram was recorded at 254nm. Then developed 
method was validated by using various parameters. 
Precision studies were carried out using parameters like 
repeatability, interday and intraday precision for both drugs. 
SD, %RSD of RP-HPLC method was under limit which shows 
that method was precise. For accuracy studied three 
replicate injections, each of three different test 
concentrations in the range of 80, 100 and 120% of labeled 
claim of formulation under study has % recovery. The 
results for recovery studies showed that results were within 
acceptable limits, above 99% and below 101%. Robustness 
studies were carried out using different analyst parameter. 
Results of robustness showed that no significant change in 
Retention time and Area under curve by small variation in 
method parameter.  
System suitability test were carried out as per USP-24 and all 
suitability parameter of both comes under acceptable limit.  
CONCLUSION 
In the present research work, a successful attempt was made 
for bioanalytical method development and validation for the 
estimation of Daunorubicin and Cytarabine in blood plasma 
by using RP-HPLC which was developed by experimentation 
based on thorough literature survey and ascertained by 
statistical parameters of sampling. The simplicity, rapidity, 
accurate and reproducibility of the proposed methods 
completely fulfill the objective of the research work of 
estimation of the drug in blood plasma. 
Selection of precipitating was based on solubility of drug in 
solvent; acetonitrile was selected as the precipitating agent. 
Liquid chromatographic system from waters comprising of 
manual injector, waters 515 pump for constant flow and 
constant pressure delivery and U.V. Vis.  Detector connected 
to data ace software for controlling the instrumentation as 
well as processing the data generated was used. Drug sample 
was extracted by precipitating method using 5ml of 
methanol for each ml of plasma sample. The proposed 
methods were found to be linear with correlation coefficient 
close to one. Precision was determined by repeatability, 
Intermediate precision and reproducibility of the drugs. The 
robustness of developed method was checked by changing in 
the deliberate variation in solvent. 
The result obtained shows the developed methods to be Cost 
effective, Rapid (Short retention time), Simple, Accurate (the 
value of SD and %RSD less than 2), Precise and can be 
successfully employed in the routine analysis of these drugs 
in bulk drug as well as in tablet dosage form. The Simplicity, 
Rapidly and Reproducibility of the proposed method 
completely fulfill the objective of this research work.    
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